Advertisement

Allogeneic amniotic epithelial cells for established bronchopulmonary dysplasia in premature, low birthweight infants: A first-in-human safety trial

  • Author Footnotes
    * Corresponding author.
    R. Lim
    Footnotes
    * Corresponding author.
    Affiliations
    The Ritchie Centre, Hudson Institute of Medical Research, Clayton, Victoria, Australia

    Department of Obstetrics and Gynaecology, Monash University, Melbourne, Victoria, Australia
    Search for articles by this author
  • A. Malhotra
    Affiliations
    The Ritchie Centre, Hudson Institute of Medical Research, Clayton, Victoria, Australia

    Pediatrics, Monash Health, Clayton, Victoria, Australia

    Monash Newborn, Monash Children's Hospital, Clayton, Victoria, Australia
    Search for articles by this author
  • J. Mockler
    Affiliations
    The Ritchie Centre, Hudson Institute of Medical Research, Clayton, Victoria, Australia

    Department of Obstetrics and Gynaecology, Monash University, Melbourne, Victoria, Australia
    Search for articles by this author
  • E. Wallace
    Affiliations
    The Ritchie Centre, Hudson Institute of Medical Research, Clayton, Victoria, Australia

    Department of Obstetrics and Gynaecology, Monash University, Melbourne, Victoria, Australia
    Search for articles by this author
  • Author Footnotes
    * Corresponding author.
      Background: Bronchopulmonary dysplasia (BPD) is a relatively common morbidity in preterm infants, especially in those born before 28 weeks of gestation. Current management of BPD, which has a significant impact on the patient, family and community, is largely supportive and no cure exists. Over the last decade, our group has shown that human amnion epithelial cells (hAECs), derived from healthy amniotic membranes can prevent and reverse lung injury in small and large animal models of adult and neonatal lung disease, including BPD.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect